saba_haq

Dr. Saba Haq (PhD HU, South Korea)

Assistant Professor
PROFILE SUMMARY

Dr. Saba completed her PhD degree in Life Science from Hanyang University, Seoul, South Korea. Her research interests include Gene Editing (CRISPR/Cas9), Molecular Biology, Cancer Biology and Therapeutics.

QUALIFICATION
PhD Life Sciences Hanyang University, South Korea 2019
MS Healthcare Biotechnology National University of Sciences and Technology (NUST), Pakistan 2014
BS Biotechnology National University of Sciences and Technology (NUST), Pakistan 2012
TEACHING EXPERIENCE
Assistant Professor Capital University of Science and Technology (CUST), Islamabad Since 2021
INDUSTRIAL EXPERIENCE
Facilitator Quality Control Department, National Institute of Health (NIH) (Pakistan) 2021
Research Assistant University of Sharjah 2020
Research Guide for Ph.D. students Hanyang University (South Korea) 2018 – 2019
HONORS & AWARDS
1. Ph.D. Scholarship from Korean Government Scholarship Program (2014-2018)
2. Stipend from National University of Sciences and Technology on GPA (2008-2012)
RESEARCH AREAS / INTERESTS
  1. Gene Editing (CRISPR/Cas9)
  2. Cancers Biology & Therapeutics
  3. Molecular Biology
  4. Cell Culture and Maintenance
  5. Post-translational protein modification
BOOK CHAPTER AUTHORED
  1. Haq, S., & Poondla, N. (2020). Genetically Engineered Probiotics. In Probiotic Research in Therapeutics (pp. 295-328). Springer, Singapore.
JOURNAL PUBLICATIONS
1. Haq, S., Das, S., Kim, D. H., Chandrasekaran, A. P., Hong, S. H., Kim, K. S., & Ramakrishna, S. (2019). The stability and oncogenic function of LIN28A are regulated by USP28. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1865(3), 599-610 (IF: 4.352)
2. Das, S., Chandrasekaran, A. P., Suresh, B., Haq, S., Kang, J. H., Lee, S. J., & Kim, K. S. (2020). Genome-scale screening of deubiquitinase subfamily identifies USP3 as a stabilizer of Cdc25A regulating cell cycle in cancer. Cell Death & Differentiation, 1-17. (IF: 8.350).
3. Haq, S., Suresh, B., & Ramakrishna, S. (2018). Deubiquitylating enzymes as cancer stem cell therapeutics. BBA-Reviews on Cancer, 1869(1), 1-10. (IF: 7.365).
4. Gopalappa, R., Song, M., Chandrasekaran, A. P., Das, S., Haq, S., Koh, H. C., & Ramakrishna, S. (2018). Efficient genome editing by FACS enrichment of paired D10A Cas9 nickases coupled with fluorescent proteins. Archives of pharmacal research, 41(9), 911-920. (IF: 2.460).
5. Haq, S., & Ramakrishna, S. (2017). Deubiquitylation of deubiquitylases. Open biology, 7(6), 170016. (IF: 3.830).
6. Das, S., Haq, S., & Ramakrishna, S. (2018). Scaffolding protein RanBPM and its interactions in diverse signaling pathways in health and disease. Discovery medicine, 25(138), 177-194. (IF: 2.174).
7. Haq, S. and Ramakrishna S. Future application of deubiquitylating enzymes for rapid and efficient cellular reprogramming. Journal of Stem Cell Research and Therapeutics, 2017, 2 (6): 184-188.
8. Jalal N, Nazeer S, Anwar N, Haq, S. (2016). Artemis inhibitor: A new approach for radiotherapy. The Journal of Pharmaceutics & Drug Delivery Research, DOI: 10.4172 / 2325-9604.C1.014 (IF: 2.5147).
9. Jalal, N., Haq, S., Anwar, N., Nazeer, S., & Saeed, U. (2014). Radiation induced bystander effect and DNA damage. Journal of cancer research and therapeutics, 10(4), 819-833 (IF: 1.410).
10. Arshad, M., Afzal, S., Zaib, B., & Haq, S. (2011). The association of NCF1 gene with the severity of Malaria. British Journal of Medical Practitioners, 4(2), 10-14.

Other Members